Video

Dr. Iqbal on Second- and Third-Line Therapies in Gastric Cancer

Author(s):

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses second- and third-line therapies in gastric cancer.

Syma Iqbal, MD, associate professor of clinical medicine, Keck School of Medicine, University of Southern California, discusses second- and third-line therapies in gastric cancer.

Physicians have a lot of options in the second-line setting, following the introduction of targeted therapies such as ramucirumab (Cyramza), says Iqbal. The VEGFR-2 inhibitor was FDA approved in 2014 as a treatment for patients with unresectable gastric cancer or gastroesophageal junction (GEJ) adenocarcinoma following fluoropyrimidine- or platinum-containing therapy. In 2017, the agent was tested in combination with cisplatin and capecitabine or 5-FU (5-fluorouracil) in the frontline setting but failed to improve overall survival in patients with HER2-negative metastatic gastric or GEJ adenocarcinoma.

Moreover, immunotherapy has made an impact in the field. Currently, pembrolizumab (Keytruda) is FDA approved in the third-line setting for patients who are PD—L1 positive. These patients have about a 15% response rate, adds Iqbal. Durability has been seen in some patients, though not commonly. The goal now, says Iqbal, is to move immunotherapy into the first- and second-line settings.

Related Videos
Paolo Caimi, MD
Jennifer Scalici, MD
Steven H. Lin, MD, PhD
Anna Weiss, MD, associate professor, Department of Surgery, Oncology, associate professor, Cancer Center, University of Rochester Medicine
Roy S. Herbst, MD, PhD, Ensign Professor of Medicine (Medical Oncology), professor, pharmacology, deputy director, Yale Cancer Center; chief, Hematology/Medical Oncology, Yale Cancer Center and Smilow Cancer Hospital; assistant dean, Translational Research, Yale School of Medicine
Victor Moreno, MD, PhD
Haley M. Hill, PA-C, discusses preliminary data for zenocutuzumab in NRG1 fusion–positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses how physician assistants aid in treatment planning for NRG1-positive non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses DNA vs RNA sequencing for genetic testing in non–small cell lung cancer and pancreatic cancer.
Haley M. Hill, PA-C, discusses current approaches and treatment challenges in NRG1-positive non–small cell lung cancer and pancreatic cancer.